| Stage I | Stage II | Stage III | Stage IV | Total |
---|---|---|---|---|---|
(N = 7955) | (N = 70333) | (N = 35773) | (N = 57469) | (N = 171530) | |
No of events, n (%) | 312 (3.92) | 13,427 (19.09) | 9662 (27.01) | 28,780 (50.08) | 52,181 (30.42) |
Median OS, months, 95% CI | 79.18 (79.18–80.46) | 58.12 (55.92–60.62) | 33.48 (32.76–34.40) | 14.82 (14.62–15.01) | 28.68 (28.32–29.08) |
HR, 95% CIa | Ref. | 5.84 (5.22–6.54) | 7.61 (6.80–8.51) | 17.49 (15.64–19.55) | NA |
Survival ratesb | Â | Â | Â | Â | Â |
 1-year, 95% CI | 97.42 (96.97–97.87) | 83.40 (83.04–83.76) | 81.91 (81.41–82.40) | 57.52 (57.05-58.00) | 74.07 (73.81–74.33) |
 2-year, 95% CI | 94.81 (94.07–95.55) | 69.13 (68.61–69.65) | 60.92 (60.20-61.66) | 33.58 (33.06–34.10) | 54.89 (54.56–55.23) |
 3-year, 95% CI | 91.81 (90.74–92.90) | 59.88 (59.26–60.51) | 48.01 (47.17–48.88) | 22.51 (22.00-23.05) | 44.21 (43.83–44.60) |
 4-year, 95% CI | 89.55 (88.18–90.95) | 54.26 (53.54–54.98) | 39.81 (38.86–40.79) | 16.82 (16.29–17.37) | 37.97 (37.54–38.40) |
 5-year, 95% CI | 85.07 (82.77–87.44) | 49.34 (48.46–50.24) | 35.56 (34.48–36.67) | 13.15 (12.57–13.76) | 33.53 (33.04–34.03) |